Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04200625 · ClinicalTrials.gov registry record
Semaglutide vs Dulaglutide on Epicardial Adipose Tissue
A clinical trial, sponsored by University of Miami.
- Completed
- Registry status
- 80
- Enrollment target
NCT04200625: Completed study, sponsored by University of Miami.
NCT04200625 is a clinical trial that has completed, run by University of Miami. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04200625 has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- 80 participants
- Enrollment target
Study Summary
Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of GLP-1 receptor agonists semaglutide and dulaglutide on EAT thickness are unknown
Primary Outcome
Ultrasound measured Epicardial Fat thickness
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2019-09-24 |
| Est. Completion | 2019-12-09 |
What the finished NCT04200625 record still lists
NCT04200625 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04200625 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04200625 about?
NCT04200625 is a clinical study titled "Semaglutide vs Dulaglutide on Epicardial Adipose Tissue". Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of GLP-1 receptor agonists...
What is the current status of trial NCT04200625?
This trial is currently completed. The enrollment target is 80 participants. The study started on 2019-09-24. Estimated completion is 2019-12-09.
Who is sponsoring clinical trial NCT04200625?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI